MOONEY CHEMICALS, INC. – Trademark Portfolio
Entity Type: 03
MOONEY CHEMICALS, INC. holds 18 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 17 filings in this category. The portfolio also extends into Class 2 (Paints) across 3 Nice Classification classes. Currently, 12 trademarks are registered. Notable registered marks include SKINO, CUR-RX, DRI-RX, SPURSO, and CEM-ALL. The owner is based in CLEVELAND, OH.
2301 SCRANTON RD.
CLEVELAND, OH
Showing of trademarks Trademarks
Trademark Classifications
MOONEY CHEMICALS, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Paints, varnishes, lacquers; preservatives against rust and against deterioration of wood
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does MOONEY CHEMICALS, INC. have?
MOONEY CHEMICALS, INC. has 18 U.S. trademarks filed with the USPTO. Of these, 12 registered, 2 abandoned, 4 cancelled.
What trademark classes does MOONEY CHEMICALS, INC. file in?
MOONEY CHEMICALS, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 2 (Paints), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are MOONEY CHEMICALS, INC.'s most well-known trademarks?
MOONEY CHEMICALS, INC.'s registered trademark portfolio includes well-known marks such as SKINO, CUR-RX, DRI-RX, SPURSO, and CEM-ALL. These are among 12 currently registered trademarks in the portfolio.
What is MOONEY CHEMICALS, INC.'s trademark registration success rate?
MOONEY CHEMICALS, INC. has a 67% trademark registration rate, with 12 out of 18 resolved applications resulting in successful registration. Currently, 0 applications are pending review.